7:30 am Morning Refreshments & Check-In
8:20 am Chair’s Opening Remarks
Examining the Evolving Landscape of Obesity from New Targets to the Clinic to Inform & Update on the Future of Weight Loss Drug Development
8:30 am Redefining Obesity & the Implications for Drug Development in the PostLancet Commission Era to Improve Patient Treatment for More Effective Weight Management
Synopsis
- Redefining obesity beyond BMI, emphasizing health outcomes and moving towards a more personalized approach based on the Lancet Commission on Obesity’s recommendations
- Prioritizing targets that address the underlying causes of clinical obesity and its complications, developing personalized therapies, and emphasizing clinical endpoints that reflect improved health outcomes
- Understanding the challenges of implementing this new approach, such as developing accurate diagnostic tools and addressing the complexities of personalized medicine as well as highlighting the significant opportunities for innovation and improved patient outcomes Charlie Harris Associate Vice President Eli Lilly
9:30 am Evaluating the Obesity Treatments In Use Using Real World Data on Patient Experience to Better Future Drugs for More Effective Weight Loss
Synopsis
- Investigating current obesity treatments through real-world patient experience data to identify areas for improvement
- Analysing patient feedback and outcomes to understand the effectiveness and limitations of existing weight loss drugs
- Informing the development of future obesity medications by leveraging real-world data insights for more targeted and successful weight management
10:00 am Morning Break & Speed Networking
Synopsis
Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in obesity drug development. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers and press releases into the pioneering research and therapeutic development
Unlocking the Power of Spatial Biology to Revolutionize Immuno-Oncology
11:00 am Why Physiologically-Regulated GLP-1 May Improve the Efficacy and Tolerability of Weight Loss Therapeutics
Synopsis
- Mimicking the physiologic secretion profile of GLP-1 to provide receptor agonism when it is needed, for improved efficacy and tolerability
- Targeting individual patient needs by developing a platform for several multi-agonist therapies
- Reducing treatment burden with a one-time, life-long therapy
11:30 am Targeting Specific Disease Populations With Multi-Agonists
Synopsis
- Tailoring dual-receptor agonists to treat a variety of metabolic diseases
- Increase weight loss efficacy by combining GLP-1 agonists with complementary coagonist mechanisms
- Improving obesity-related comorbidities with multi-agonists
12:00 pm Session Reserved
12:30 pm Mechanistic Insights Into Survodutide, a Dual Glucagon/GLP-1 Receptor Agonist, for Obesity Treatment
Synopsis
- Exploring the potential of dual and triple receptor agonists targeting multiple pathways involved in energy regulation, such as GLP-1, GIP, and glucagon receptors, to achieve weight loss with improved tolerability profiles
- Evaluating their clinical and metabolic benefits, and their potential to address gastrointestinal side effects while maintaining potent weight loss efficacy
- Understanding receptor interactions and signalling pathways used by these multireceptor agonists to optimise their therapeutic potential and identify patient populations that may benefit from these innovative approaches
1:00 pm Lunch & Networking
Investigating Novel Therapeutic Targets Beyond GLP-1 to Explore the Future of More Efficacious Obesity Treatment
2:00 pm Adding a Gut-Liver Targeted Metabolic Modulator Using Novel Inflammatory Pathways for Increased Metabolic Benefits
Synopsis
- Targeting novel inflammatory pathways within the gut-liver axis presents a promising strategy for developing innovative metabolic modulators
- Leveraging these modulators in combination with existing therapies, such as GLP-1 receptor agonists, to offer enhanced metabolic benefits, including improved weight loss, glycemic control, and reduced hepatic steatosis
- Providing a treatment with better ease of patient use for better weight maintenance
2:30 pm Session Reserved
Maintaining Muscle Mass & Strategies to Prevent Sarcopenia in Obesity Treatment
2:40 pm Muscle-Targeted Therapeutics That Can Be Combined with Obesity Drugs to Improve the Quality of Weight Management
Synopsis
- Addressing the concern of muscle loss, as a side effect of GLP-1 medications, through the development of muscle preservation and stimulation approaches
- Exploring the synergistic potential of combining these muscle stimulants with existing obesity therapies to improve weight loss outcomes
- Optimizing the development of safe and effective muscle stimulants by focusing on specific targets and innovative delivery mechanisms
3:10 pm Afternoon Networking Break & Poster Session
Synopsis
Connect with peers in a relaxed atmosphere and continue to forge new and existing relationships while exploring the latest in obesity and weight loss research and advancements. To submit a poster, please contact info@hansonwade.com
4:10 pm Targeting the TGF-Beta Superfamily With Extended Half-Life Antibodies to Enable Improved Quality of Weight Loss
Synopsis
- Long half life antibodies can reduce dose volume and frequency without sacrificing efficacy
- Inhibition of myostatin can counter lean mass loss and potentially enable improved patient experience and outcomes
- Additional targets and combinations of targets within the TGF-beta superfamily can enable further improvements in weight loss quality
4:40 pm Panel Discussion: Genetic & Phenotypic Based Approaches to Further Precision Medicine to More Effectively Combat Obesity
Synopsis
- Identifying the key biomarkers and patient characteristics that predict treatment response and adverse events to different obesity medications and interventions.
- Exploring the ethical and social implications of personalized obesity treatment, including access, equity, and the potential for disparities in care. Developing strategies for integrating personalized medicine approaches into routine clinical practice, including the development of user-friendly tools and resources for healthcare providers and patients